Status as of October 2026: the first partial-reprogramming therapy in humans, Life Biosciences' ER-100 (OSK factors delivered into the eye), was cleared by the FDA in January 2026 and dosed its first participant in June 2026, in a Phase 1 for glaucoma and non-arteritic anterior ischemic optic neuropathy, a disease indication rather than age reversal. An approval before the end of 2029 would need Phase 2 and Phase 3 inside three and a half years; the comparable ophthalmic gene therapy Luxturna took ten years from first-in-human (2007) to approval (2017). No reprogramming company has an aging indication on file with the FDA's drug center, and the only acceptance of lifespan or healthspan as an indication by any regulator so far is the FDA's veterinary center for dog drugs. Which species gets there first (mine): /w0lph/which-species-will-get-the-first-re